Venekra is mainly used in the treatment of some adult acute myeloid leukemia, which can effectively prolong the time to complete remission of the patient’s disease, and has better clinical efficacy. Venekra is used in combination with azacitidine in adult patients with newly diagnosed acute myeloid leukemia who are unable to receive strong induction chemotherapy due to comorbidities, or who are ≥75 years of age. Clinical trials have shown that this product has a favorable clinical outcome by shortening the time to reach complete patient and significantly prolonging the duration of complete remission. Common adverse reactions after the use of this product nausea, constipation, diarrhea, thrombocytopenia, bleeding, neutropenia, peripheral edema, fatigue, vomiting, etc. Allergy to this product is prohibited. Please adhere to the medication under the guidance of the physician in accordance with the medical advice, if there is obvious discomfort, please consult your physician.